Please login to the form below

Not currently logged in

Dassault Systèmes completes acquisition of Medidata

Medidata will now operate as a separate brand of DS

Dassault Systems

Dassault Systèmes has completed the acquisition of Medidata, a digital clinical solutions company with a leading clinical trial platform. 

The acquisition of Medidata will provide Dassault with a leading expertise in cloud-based solutions, which aid in the smarter development and commercialisation of treatments coming through the pipeline.

“Together with Medidata’s solutions and its great talents that we are delighted to welcome, we bring an unmatched combination of assets to reinforce our vision, science-based culture, and life sciences industry knowledge and know-how. Medidata will be a core brand in our information intelligence domain,” said Bernard Charlès, Vice Chairman and CEO, Dassault Systèmes.

“By combining data intelligence and simulation, we power smarter therapeutics for healthier people. The inclusive and multi-discipline 3DEXPERIENCE platform will be key for healthcare innovators to anticipate and address the needs of the industry’s transformation toward affordable precision healthcare in the 21st century.

"The virtual world will push the bounds of possibilities to transform not only research and science, but also the entire pharmaceutical and medical device industry and medicine, in general. We made virtual twins of cars and airplanes possible. We will do the same for the human body.”

Medidata will now operate as a Dassault Systémes brand, powered by the 3DExperience platform. The life sciences industry will become Dassault’s second largest business, after transportation and mobility, while advancing sustainable innovation in the industry through the use of biological, chemical and materials science, clinical trials and real-world data on the cloud.

Under the terms of the agreement, Dassault Systémes acquires all of the issued and outstanding common shares of Medidata, for $92.25 per share in cash, representing a total value of around $5.8bn.

31st October 2019

From: Marketing



COVID-19 Updates and Daily News

Featured jobs


Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...